October 22–23, 2019 — San Francisco, CA

Event: BIO Investor Forum

Topic: Public Policy Outlook on Biotech Investment from China

According to Pitchbook, Chinese venture capital investment in U.S. biotechs has declined more than 60% in the first half of 2019. The increased review of transactions by the Committee on Foreign Investment in the United States (CFIUS), national security concerns and trade negotiations have created a new landscape for cross-border business. During this plenary luncheon, the speakers will explore how biotech companies can continue to raise capital, examine the proposed rulemaking from CFIUS in the coming months, and discuss how companies can remain innovative while CEOs and investors navigate these changes.

Panelists

  • Helen Chen, Managing Director, L.E.K. Consulting
  • Cameron Arterton, Vice President, Tax Policy, Biotechnology Innovation Organization
  • Joshua Gruenspecht, Of Counsel, Wilson Sonsini Goodrich & Rosati
  • James Huang, Managing Partner, Kleiner Perkins Caufield & Byers China

Date/Location:     
Tuesday, October 22, 2019     
The Westin St. Francis
San Francisco, CA

Time: 12:30-1:25 p.m.

About Helen Chen
Helen Chen is a Greater China Managing Partner of L.E.K. based in Shanghai. She was a member of L.E.K.’s Global Leadership Team from 2012 to 2016. Helen is also head of L.E.K.’s China and Asia Biopharmaceuticals & Life Sciences practice and a Director of the firm’s Asia-Pacific Life Sciences Centre of Excellence. She has extensive case work and industry experience covering the full biopharmaceutical and medical devices value chain.

Helen has 30 years of consulting and industry experience in the U.S. and Asia markets and has resided in China since 2000. She helps companies expand their presence in China and leverages China’s resources to improve their global businesses. She is a frequent speaker and author on the opportunities and issues in China’s Healthcare and Life Sciences sectors.

BIO Investor Forum
This investor forum explores investment trends and opportunities in life sciences, with a focus on venture-stage growth and emerging public companies as well as those poised to join the growth “watch list” in 2020. With a mission to support industry-wide success, this event strives to present a broad and unbiased view of investment opportunities.

About L.E.K. Consulting
L.E.K. Consulting is a global management consulting firm that uses deep industry expertise and rigorous analysis to help business leaders achieve practical results with real impact. We are uncompromising in our approach to helping clients consistently make better decisions, deliver improved business performance and create greater shareholder returns. The firm advises and supports global companies that are leaders in their industries — including the largest private- and public-sector organizations, private equity firms, and emerging entrepreneurial businesses. Founded in 1983, L.E.K. employs more than 1,400 professionals across the Americas, Asia-Pacific and Europe. For more information, go to www.lek.com.